On the other hand, the degree of cardiac systolic dysfunction and injury following doxorubicin treatment were comparable between HER2-positive and HER2-negative breast cancer patients despite the difference of oxidative stress level between these two groups. The gene discussed is ERBB2; the disease is breast carcinoma.